{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["50(1)"],"submitter":["Thomas L"],"pubmed_abstract":["Hyperphosphatemia results from an imbalance in phosphate (Pi) homeostasis. In patients with and without reduced kidney function, hyperphosphatemia is associated with cardiovascular complications. The current mainstays in the management of hyperphosphatemia are oral Pi binder and dietary Pi restriction. Although these options are employed in patients with chronic kidney disease (CKD), they seem inadequate to correct elevated plasma Pi levels. In addition, a paradoxical increase in expression of intestinal Pi transporter and uptake may occur. Recently, studies in rodents targeting the renal Na+/Pi cotransporter 2a (Npt2a), responsible for ∼70% of Pi reabsorption, have been proposed as a potential treatment option. Two compounds (PF-06869206 and BAY-767) have been developed which are selectiv"],"journal":["Biochemical Society transactions"],"pagination":["439-446"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9022968"],"repository":["biostudies-literature"],"pubmed_title":["Npt2a as a target for treating hyperphosphatemia."],"pmcid":["PMC9022968"],"pubmed_authors":["Thomas L","Rieg T","Dominguez Rieg JA"],"additional_accession":[]},"is_claimable":false,"name":"Npt2a as a target for treating hyperphosphatemia.","description":"Hyperphosphatemia results from an imbalance in phosphate (Pi) homeostasis. In patients with and without reduced kidney function, hyperphosphatemia is associated with cardiovascular complications. The current mainstays in the management of hyperphosphatemia are oral Pi binder and dietary Pi restriction. Although these options are employed in patients with chronic kidney disease (CKD), they seem inadequate to correct elevated plasma Pi levels. In addition, a paradoxical increase in expression of intestinal Pi transporter and uptake may occur. Recently, studies in rodents targeting the renal Na+/Pi cotransporter 2a (Npt2a), responsible for ∼70% of Pi reabsorption, have been proposed as a potential treatment option. Two compounds (PF-06869206 and BAY-767) have been developed which are selectiv","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2025-04-22T01:19:26.876Z","creation":"2024-10-19T05:54:42.038Z"},"accession":"S-EPMC9022968","cross_references":{"pubmed":["34994388"],"doi":["10.1042/BST20211005"]}}